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The transcriptional repressor B cell lymphoma 6 (BCL6) controls a large transcriptional network that is required for the for-
mation and maintenance of germinal centers (GC). GC B cells represent the normal counterpart of most human B-cell lym-
phomas, which are often characterized by deregulated BCL6 expression or BCL6-mediated pathways. BCL6 suppresses gene 
transcription largely through recruitment of its co-repressors through its distinct repression domain. Understanding the precise 
biological roles of each repression domain in normal and malignant B cells is helpful for development of targeted inhibition of 
BCL6 functions that is emerging as the basis for design of anti-lymphoma therapies. This review focuses on recent progress in 
the molecular mechanisms of action of BCL6 in B cells and discusses remaining unresolved questions related to how these 
mechanisms are linked to normal and malignant B cell development. 
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The germinal center (GC) reaction, involving generation of 
high-affinity memory B cells and plasma cells, is the basis 
of T-dependent humoral immunity against foreign patho-
gens [1]. The GC reaction is highly dynamic and coordi-
nated by multiple immune cell types including T cells, B 
cells and follicular dendritic cells [2]. GCs are transient mi-
crostructures formed within the follicles of secondary lym-
phoid tissues during the GC reaction. GC B cell develop-
ment is highly dynamic and instructed by specific and intri-
cate transcriptional programs [3]. Notably, some of the core 
molecular mechanisms driving these programs are also in-
volved in B-cell malignant transformation. Indeed, the ma-
jority of human mature B cell lymphomas originate from 
GC B-cells [4]. 
The transcriptional repressor B cell lymphoma 6 (BCL6), 
originally identified as encoded by a frequently translocated 
locus in diffuse large B cell lymphomas (DLBCLs) [5], 
serves as a master regulator of the GC reaction [6,7]. BCL6 
is essential for the development and function of both GC B 
cell and T follicular helper (Tfh) cell [8–10], a specialized T 
helper subtype which supports B cells during the GC reac-
tion. Loss of BCL6 in each cell type results in abrogation of 
the GC reaction. BCL6 acts as an oncogene in GC-derived 
B-cell lymphoma, which is usually characterized by dereg-
ulated BCL6 expression due to chromosomal translocation 
or mutations of its promoter, or feature genetic lesions in 
pathways normally regulated by BCL6 [11,12]. 
From the biochemical mechanism standpoint, BCL6 ex-
erts its effects mostly through recruitment of various 
co-repressor complexes [13]. These different co-repressor 
complexes appear to suppress distinct gene sets, perhaps 
mediating different activities of BCL6 in various immune 
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cells. This notion has been in part supported by studies using 
inhibitors that selectively disrupt the co-repressors binding to 
the BCL6 BTB (BR-C, ttk and bab) domain [14,15]. How-
ever, the link between the transcriptional mechanisms of 
action of BCL6 with its biological actions in the immune 
system remains to be further characterized. In recent years, 
two new mouse models designed to dissect the biochemical 
mechanisms of action of BCL6 have provided critical in-
sight into the ways that BCL6 can control the phenotype of 
B cells during the GC reaction [16,17]. 
1  GC B cell development and B cell lym-
phomagenesis 
Formation of GCs is central to the establishment of long-lived, 
high-affinity T cell-dependent B cell responses [1]. The first 
step towards GC formation is activation of naïve B cells by 
exogenous T-cell dependent antigen in the follicles of pe-
ripheral lymphoid tissues. Next, antigen-engaged B-cells 
migrate to the border between the follicles and the T cell 
zone or interfollicular zones, where they undergo prolifera-
tion and interact with cognate Tfh cells within 1–3 days 
after stimulation [18–21]. B-cells can then differentiate into 
extrafollicular plasma cells and leave the follicle to generate 
low-affinity antibodies, or alternatively can enter the GC 
pathway [22]. These early GC precursor B cells (i.e. pre-GC 
B cells) begin to up-regulate expression of BCL6 protein 
and move toward the center of lymphoid follicles [20,21]. 
BCL6 up-regulation in pre-GC B cells contributes to their 
sustained interactions with Tfh cells and is required for their 
further differentiation in the lymphoid follicles. Pre-GC B 
cells finally aggregate into early GC clusters at day 4 
post-immunization. 
Once early GCs are established, B cells undergo rapid 
proliferation, resulting in massive expansion of GCs. By 
seven days the GC becomes fully formed and is polarized 
between two microenvironments called the dark zone and 
the light zone. Dark zone B cells (centroblasts) undergo 
clonal expansion and somatic hypermutation (SHM) of 
immunoglobulin variable region to generate mutant clones 
with a broad range of affinities for the antigen, and then 
migrate towards the light zone [2,22,23]. Within the light 
zone GC B-cells (centrocytes) undergo three main differen-
tiation processes: the positive selection of B cells expressing 
high-affinity immunoglobulin by Tfh cells, the process of 
class-switch recombination (CSR) to produce various types 
of immunoglobulin and the initiation of terminal differenti-
ation into memory cells or plasma cells. Some centrocytes 
may re-enter the dark zone to undergo further rounds of 
proliferation, affinity maturation and selection. 
Single and double strand DNA damage mediated by ac-
tivation induced cytosine deaminase (AICDA) is required 
for SHM and CSR during the GC reaction and essential to 
permit immunoglobulin mutagenesis and maturation. How-
ever, AICDA can also cause genetic alterations at genes 
beyond the immunoglobulin loci, resulting in the deregu-
lated or ectopic expression of oncogenes or the inactivation 
of tumor suppressors. Accordingly, the majority of mature 
B cell lymphomas, including follicular lymphomas (FLs), 
DLBCLs and Burkett’s lymphomas (BLs), arise from GC B 
cells [4], as shown by the presence of somatically mutated 
immunoglobulin genes in their genomes. Importantly, many 
of the somatic mutations occurring in these lymphomas are 
associated with genes that exhibit strong differential regula-
tion during GC B cell development, such as MYC, BCL6 
and PRDM1(which encodes B lymphocyte-induced mat-
uration protein 1) [24]. Exploration of the functions of 
these genes during normal GC B cell development may thus 
be likely to provide a better understanding of the pathogen-
esis of B-cell lymphomas.  
2  BCL6: a master transcriptional regulator of 
GC B-cell development 
GC B cell differentiation is tightly controlled by various 
transcription regulators including BCL6 [3,24]. In the B-cell 
lineage, BCL6 protein is induced and highly expressed in 
centroblasts, and its expression is maintained in most cen-
trocytes [25]. Bcl6-deficient mice fail to form GCs and 
hence are unable to generate high-affinity antibodies, 
demonstrating an essential requirement of this transcrip-
tional factor in the establishment and/or maintenance of 
GCs [6,7,26]. One of the best characterized biological func-
tions of BCL6 in centroblasts is to facilitate simultaneous 
rapid proliferation and tolerance of genomic damage occur-
ring during clonal expansion and somatic hypermutation. 
BCL6 mediates these effects by directly repressing DNA 
damage sensing and checkpoint genes such as DNA damage 
sensor ATR (ataxia telangiectasia and Rad3 related), TP53 
(tumor protein p53) tumor suppressor and cell cycle arrest gene 
CDKN1A (cyclin-dependent kinase inhibitor 1A) [27–29]. In 
addition, BCL6 blocks premature activation by T cells or 
other soluble signals through inhibiting a number of path-
ways involved in B-cell activation in T-cell dependent im-
mune [11–13]. This function of BCL6 may be important to 
prevent centroblasts to exit from the GC before they com-
plete the phase of proliferative expansion and of antibody 
affinity maturation. Finally, BCL6 represses a number of 
genes required for the differentiation of B cells into plasma 
cells, including PRDM1, a transcription factor that is crucial 
for plasma cell development [30,31].  
Although the importance of BCL6 in determining the GC 
phenotype has been well defined, the functions of this pro-
tein in regulating the fate of pre-GC B cell have only re-
cently begun to be understood. Recent studies using 
Bcl6-reporter mice and high-resolution intravital cellular 
imaging have established a critical role for BCL6 in pre-GC 
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events [20,21]. BCL6 protein is first detected in the interfol-
licular zone in a small subset of activated antigen-engaged 
B cells that have been successfully engaged by Tfh cells. 
Many of these BCL6-positive cells (i.e. pre-GC B cells) are 
destined to the GC pathway. BCL6 up-regulation appears to 
be important for pre-GC B cell to form sustained interaction 
with cognate Tfh cells and move towards the center of the 
follicle. BCL6 seems to drive pre-GC B cell migration at 
least in part through directly inhibiting the trafficking factors 
Sphingosine 1-phosphate receptor 1 (S1PR1) and GPR183, 
which encodes G protein-coupled receptor 183 [21,31]. 
These new findings point to multifaceted biological func-
tions of BCL6 in the GC response. 
BCL6 must be switched off for GC B cell to exit from 
the GC and undergo terminal differentiation [32]. Deregu-
lated BCL6 expression, due to chromosomal translocation 
or mutations of its own promoter, or genetic alterations in 
pathways normally regulated by BCL6, is commonly asso-
ciated with DLBCLs and less frequently associated with 
FLs [11,33,34]. The pro-survival and proliferation functions 
of BCL6 appear to make GC B cells prone to malignant 
transformation. Mice constitutively expressing BCL6 in GC 
B cells develop DLBCL with features similar to the human 
tumors [35]. Indeed, most GC-derived lymphomas are de-
pendent on the expression and transcriptional activity of 
BCL6 [14,31]. Thus, targeted inhibition of BCL6 functions 
has been proposed as a promising therapeutic strategy for 
GC-derived lymphomas.   
3  Biochemical mechanisms of action of BCL6  
The transcriptional repression activity of BCL6 is depend-
ent on its binding to co-repressor proteins, and there are 
many co-repressors that BCL6 can partner with. BCL6 re-
cruits co-repressors mainly via its conserved N-terminal 
BTB/POZ (Pox virus and Zinc finger) domain and a middle 
unstructured region (often called the second repression do-
main or “RD2” domain) [13]. Both the BTB and RD2 do-
main recruit distinct sets of co-repressors (Figure 1). The 
BCL6 BTB domain forms an obligate homodimer to create 
two identical and symmetrical extended lateral grooves that 
form docking sites for the co-repressor proteins SMRT (si-
lencing mediator of retinoid and thyroid receptor), 
NCOR(nuclear receptor corepressor) and BCOR (BCL6 
corepressor) (Figure 1) [36,37]. NCOR and SMRT are 
highly conserved scaffold/adaptor proteins, both of which 
can individually form a stable complex with HDAC3 (his-
tone deacetylase 3), TBL1 (transducin-beta-like protein 1), 
TBLR1 (transducin-beta-like related protein 1) and GPS2 
(G protein pathway suppressor 2) [38]. Both NCOR and 
SMRT bind to BCL6 via a conserved 17-residue BCL6 
binding domain (BBD) [37]. BCOR forms a completely 
different type of complex than NCOR and SMRT [39]. 
 
Figure 1  Schematic representation of key transcriptional mechanisms of 
action of BCL6. BCL6 exerts its repression activity largely through the 
recruitment of co-repressors mainly via N-terminal BTB domain and sec-
ond middle RD2 domain. The BTB domain co-repressors include SMRT, 
NCOR and BCOR, whereas the RD2 domain binds to HDAC2 and 
MTA3/NurD complex, perhaps other unknown con-repressors. BCL6 
recruit distinct co-repressor complex to different subsets of targets.  
Specifically, BCOR associates with a polycomb/ubiquitin 
ligase complex containing RING1, RYBP, NSPC1, RNF2, 
FBXL10 and Skp1 (S-phase kinase-assocated protein 1) 
[40]. The BBDs of NCOR and SMRT are identical, whereas 
the BCOR BBD is completely different, yet all three bind to 
the BCL6 BTB lateral groove in perfectly overlapping con-
figurations [37,39]. BCL6 appears to recruit two distinct 
repression complexes at promoters and enhancers via its 
BTB domain [41]. At promoters, BCL6 dimers can recruit a 
unique ternary BCOR-SMRT/NCOR complex to effectively 
repress transcription in a repressed chromatin environment. 
At enhancers, BCL6 selectively recruits HDAC3-containing 
SMRT/NCOR complex to functionally inactivate these  
elements through H3K27 deacetylation. The RD2 domain 
recruits HDAC2 (histone deacetylase 2) and MTA3/NuRD 
(nucleosome remodeling and deacetylase) complex, and 
possibly other co- repressors (Figure 1) [30,42]. Interest-
ingly, the co-activator p300 can bind and acetylate the RD2 
domain at its KKYK motif and inhibit its transcription ac-
tivity [42]. Recently, a 45-amino acid region compassing 
KKYK motif was identified to interact with HDAC2 and 
MTA3/NurD complex [17]. This region displayed a similar 
repression effect as full-length RD2. Finally, BCL6 recruits 
the co-repressor CtBP1 (C-terminal binding protein 1) via 
both the BTB and RD2 domain [43]. 
The transcriptional repression activity of BCL6 requires 
its binding to specific DNA elements. Recently, whole-  
genome chromatin immunoprecipitation plus sequencing 
(ChIP-seq) analysis identified genome-wide BCL6 binding 
sites [33,41,44]. BCL6 binding sites were shown to be sig-
nificantly enriched in the BCL6 consensus binding motif 
TTCCT(A/C)GAA that was initially identified in vitro by 
examining the ability of recombinant BCL6 protein to bind 
to synthetic oligonucleotides. Hence BCL6 is often directly 
recruited to these regions through its C-terminal zinc fin-
gers. BCL6 can also bind to DNA indirectly through inter-
acting with other BTB-containing transcription factors. For 
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instance, BCL6 binding to the promoter of two genes 
(CDKN1A and BCL2) is dependent on ZBTB17 (also known 
as Miz1) [29,44]. BCL6 is recruited to the promoter of 
PRDM1 through BACH2 (BTB and CNC homologue 2) [45].  
Meanwhile, ChIP-seq analysis also revealed that the 
BCL6 activities are associated with other transcription fac-
tors that are important regulators of GC B cell development. 
This is evident by this fact that BCl6 binding sites are sig-
nificantly coincident with the cistrome of these proteins 
including MYB (v-myb myeloblastosis viral oncogene  
homology), IRF8 (interferon-regulatory factor 8) and 
BACH2 [41,44,45]. BCL6 seems to antagonize or synergize 
these transcription factors in programing the GC phenotype. 
For instance, BCL6 cooperates with BACH2 to suppress 
PRDM1 transcription and terminal differentiation [45]. Fi-
nally, BCL6 may suppress transcription by competing for 
binding with STAT family transcriptional activators, which 
share quite similar binding sites with BCL6 [6,16,46]. In 
summary, BCL6 serves as a transcriptional repressor 
through DNA binding and recruitment of co-repressor com-
plexes.  
4  The BCL6 BTB domain is critical for prolif-
eration and survival of mature GC B-cells  
Although the BCL6 target genes are well defined [33,41,44], 
the precise functions of separate BCL6 repression domain is 
less clear. BCL6 appears to recruit distinct co-repressor 
complex to different subsets of targets (Figure 1) [47,48], 
suggesting that  transcriptional  programming by  
BCL6 may be finely compartmentalized through distinct 
domains. A SMRT-based cell penetrating BCL6 peptide 
inhibitor (BPI), which is designed to dissociate the BCL6 
BTB domain and its co-repressors [14], was able to induce 
expression of genes such as ATR, TP53 and CDKN1A in-
volved in DNA damage and cell cycle checkpoints in pri-
mary GC B cells and DLBCL cells, but did not affect ex-
pression of BCL6 target genes involved in differentiation 
such as PRDM1 [48]. Consistent with this, BPI administra-
tion prevented GC formation in mice and induced cell cycle 
arrest and apoptosis in DLBCL cells [14,47]. These studies 
suggest that the BTB domain is especially required for cell 
survival and proliferation.  
A genetically engineered strain of mice was generated to 
express a mutant form of BCL6 that is unable to bind to 
SMRT, NCOR and BCOR, but is otherwise functionally 
intact, further supporting this notion [16]. These mice only 
formed very small GCs in response to T-cell dependent an-
tigen stimulation due to a severe defect in GC B cell prolif-
eration and survival. Further ChIP-seq studies in primary 
human GC B-cells demonstrated that BCL6 binds to key 
checkpoint genes ATR, TP53, and CDKN1A together with 
SMRT and/or BCOR [16]. Hence, the role of BCL6 as a 
regulator of cell survival and proliferation is principally 
mediated through the BTB domain and is mostly relevant to 
its physiological actions in GC B-cells (Figure 2). The same 
mechanism is maintained during tumorigenesis, as demon-
strated by the fact that GC-derived lymphomas are sensitive 
to the BCL6 BTB inhibitors [14,15,49]. Unexpectedly, BTB 
loss of function did not result in significant impairment of 
Tfh cell development and function as well as aberrant dif-
ferentiation of other T helper subtypes [16]. All tested in-




Figure 2  The proposed biochemical mechanisms of action of BCL6 during GC B cell development. The development of GC B cells is a sequential and 
complex process, and tightly controlled by BCL6. The BTB domain is critical for survival and proliferation of mature GC B-cells, whereas the RD2 domain 
plays an essential role in the development and clustering of early GC-committed B-cells. The role of the RD2 domain is mature GC B cells remains to be 
further investigated. 
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by macrophages derived from BTB mutant mice. Accord-
ingly, these animals lived normal, healthy lives and dis-
played no evidence of the lethal inflammatory disease that 
is characteristic of BCL6 deficient mice [6,16]. Therefore, 
the molecular functions of BCL6 in T cells and macrophag-
es are less dependent on the BTB domain repression func-
tion. BCL6 competing for binding with STAT family pro-
tein may present a dominant biochemical function of BCL6 
in restricting inflammatory gene expression [16]. Other un-
known repression mechanisms, perhaps through the RD2 
domain, may compensate for BTB loss of function to main-
tain the phenotype of T cells. 
5  The BCL6 RD2 domain is essential for 
pre-GC B-cell differentiation  
Recent studies have defined an essential role of BCL6 in 
pre-GC events, especially for sustained T-B interaction and 
pre-GC B cell migration [21]. However, how BCL6 acts on 
these pre-GC B-cells remains unknown. BTB-mutant B 
cells can still form early GCs [16], indicating that BTB re-
pression function is dispensable for pre-GC B-cell devel-
opment (Figure 2). However, mice engineered to express a 
Bcl6 mutant that lost RD2 domain repression function ex-
hibit a complete loss of GC formation but retain normal 
extrafollicular responses [17]. High-resolution intravital 
cellular imaging showed that RD2-mutant antigen-engaged 
B-cells can normally migrate to the interfollicular zone and 
interact with cognate T helper cells after immunization. 
However, these cells failed to complete early GC-commit- 
ment differentiation and coalesced as nascent GC aggre-
gates [17]. The profound defect in early pre-GC differentia-
tion in RD2-deficent B cells best explains the complete ab-
rogation of GC formation in Bcl6-deficent mice and empha-
sizes the importance of Bcl6 in early GC B-cell commit-
ment (Figure 2). RD2 controls migration at least in part 
through directly suppressing expression of the key migra-
tion factor GRP183 [17], down-regulation of which is criti-
cally important for B-cell migration into the follicle center. 
In addition, BCL6 directly represses S1PR1 and indirectly 
induces S1PR2 expression. S1PR1 enables B cells to move 
out of the follicles, whereas S1PR2 confines B cells to an 
S1P-low niche in the center of follicles [50]. Through dy-
namic regulation and equilibrium of S1PR1 and S1PR2, the 
BCL6 RD2 domain seems to enable “capture” of B-cells 
within follicles to promote their clustering into an S1P-low 
region. 
From the mechanistic standpoint, the BCL6 RD2 domain 
suppresses the transcription of the GPR183 and S1PR1 
genes by recruiting HDAC2, but not MTA3/NuRD to the 
enhancer active mark H3K27ac at their distal regulatory 
elements [17]. Collectively, the BCL6 RD2 domain medi-
ates early steps in commitment to the GC fate and clustering 
into nascent GCs, whereas the BCL6 BTB domain is re-
quired to maintain the proliferation and survival by repress-
ing genes during the later GC stage (Figure 2). These find-
ings suggest a model of sequential and biochemically dis-
tinct biological functions of BCL6 at different GC B-cell 
developmental stages.  
6  Conclusions and perspectives   
Recent studies on the mechanisms of action of BCL6 are 
clarifying important questions regarding the stages and bi-
ochemical mechanisms through which BCL6 controls GC 
B-cell development. It is becoming clear that the BTB and 
RD2 repression domains have distinct effects on the pheno-
type of B cells during the GC reaction (Figure 2). Interest-
ingly, the BTB and RD2 domains have limited effects on 
the phenotype of T cells and macrophage. These studies 
point towards striking biochemical specificity in BCL6 con-
trol of humoral and innate immune-cell phenotypes and 
provide a new paradigm for transcription factor functional 
diversification.  
Although the BCL6 RD2 domain is critical in regulating 
the fate of pre-GC B cells, its precise roles in B cells within 
established GCs remain to be answered (Figure 2). The 
BCL6 RD2 was reported to recruit MTA3-NurD complex to 
suppress PRDM1 transcription to prevent terminal differen-
tiation of B cells into plasma cells in cultured lymphoma 
cells, suggesting that the RD2 domain might be important to 
prevent terminal differentiation of B-cells in established 
GC. The RD2 co-repressor MTA3 was found to be dispen-
sable to inhibit genes implicated in cell cycle and apoptosis; 
however we cannot exclude the possibility that other un-
known RD2 co-repressors modulate proliferation and sur-
vival of GC B-cells as well as lymphoma. The new mice 
model in which RD2 loss of function is specifically intro-
duced in mature GC B-cells are urgent to assess these ques-
tions. Elucidation of new functions of RD2 domain in B cell 
lymphomas may lead to the identification of novel thera-
peutic targets for these diseases. Finally, it is possible that 
both BTB- and RD2-associated co-repressors bind to some 
BCL6 target sites and failure to recruit one or the other of 
each domain-specific co-repressor do not sufficiently impair 
its repression function. The biological importance of this 
biochemical mechanism needs to be further examined. Per-
haps this is required for BCL6 to prevent premature activa-
tion.  
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